|
Risk factor |
Crude HR (95% CI) |
Adjusted HR (95% CI)
Time period ≤ 11 months Time period > 11 months |
| d4T vs. AZT/TDF in regimen |
1.62 (1.14 – 2.30) |
1.41 (0.82 – 2.44) |
2.64 (1.56 – 4.46) |
| NVP vs. EFV in regimen |
1.53 (0.98 – 2.38) |
- |
- |
| CD4 < 200 vs. CD4 ≥ 200 cells/mm3 |
3.38 (1.72 – 6.65) |
1.14 (0.45 – 2.90) |
4.42 (1.62 – 12.1) |
| Weight ≥ 60 vs. < 60kg |
1.82 (1.26 – 2.65) |
1.22 (0.71 – 2.11) |
2.40 (1.43 – 4.04) |
| Female vs. male |
1.34 (0.93 – 1.95) |
1.26 (0.59 – 2.70) |
1.56 (0.86 – 2.85) |
| WHO stage I/II/III vs. IV |
0.96 (0.56 – 1.58) |
- |
- |
| Age (per year) |
1.01 (1.26 – 2.66) |
0.98 (0.95 – 1.02) |
1.03 (1.00 – 1.05) |
| d4T vs. AZT/TDF in regimen*Time period |
0.98 (0.97 – 1.00) |
- |
- |
| d4T vs. AZT/TDF in regimen*Weight category |
2.61 (1.85 – 3.66) |
- |
- |
| NVP vs. EFV in regimen*Time period |
0.96 (0.95 – 0.99) |
- |
- |
| WHO stage I/II/III vs. IV*Time period |
0.96 (0.95 – 0.98) |
- |
- |
| CD4 < 200 vs. CD4 ≥ 200 cells/mm3*Time period |
1.00 (0.93 – 1.02) |
- |
- |
HR – Hazards ratio; 95% CI – 95% Confidence interval; NVP – Nevirapine; EFV – Effavirenz; AZT – Zidovudine; d4T – Stavudine; T`DF – Tenofovir; Weight category –
weight ≥ 60 vs. < 60kg.